Vanda surges after FDA approval for antipsychotic drug

Vanda Pharmaceuticals

20/02/2026 23:35

** Shares of drugmaker Vanda Pharmaceuticals' VNDA.O rise 34.7% to $7.77 in extended trading

** U.S. FDA approves co's antipsychotic drug Bysanti

** Drug aimed at treating mental health conditions schizophrenia and acute bipolar I disorder

** Approval comes with FDA's most serious warning of increased risk of death in elderly patients with dementia-related psychosis

** In 2025, stock rose 84.1%

(Reporting by Anhata Rooprai in Bengaluru)

((Anhata.Rooprai@thomsonreuters.com))